Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2012

View Archived Issues

Peptide inhibitor nanoparticles reduce beta-amyloid aggregation in preclinical study

NME protects human bone marrow progenitor cells against radiation

Endocyte to file conditional MAAs in E.U. for anticancer therapeutic and imaging agent

Cell>Point receives SPA agreement from FDA for imaging agent

HIV peptide-loaded dendritic cells evaluated in DALIA trial

Alkermes Pharma Ireland withdraws megestrol MAA

Oncothyreon starts phase I ONT-10 cancer vaccine trial

BioFocus, Argenta and AstraZeneca enter new research agreement

Okairos launches NIH-funded phase I/II trial of HCV vaccine

Epizyme achieves preclinical milestone in mixed-lineage leukemia

Phase II program for heart failure to proceed

Threshold Pharmaceuticals treats first patient in multiple myeloma study

Millennium Pharmaceuticals designs novel PI3K and mTOR inhibitors

FDA approves first effervescent osteoporosis drug

New metabotropic glutamate mGlu2 receptor antagonists developed

New apoptosis inducers divulged

Scientists from Varinel discover novel iron chelators

Domain Therapeutics announces new funding for schizophrenia project

Intercell kicks off phase II/III study of vaccine candidate

Foamix product demonstrates efficacy in phase II trial in impetigo

Novel potential hepatitis C therapies identified at Bristol-Myers Squibb

Boehringer Ingelheim patents new bradykinin B1 receptor antagonists

Novel mineralocorticoid receptor antagonists presented by KBP BioSciences

Amgen reports new myostatin-binding antibodies

Shire withdraws BLA for Fabry's disease therapy

First oral contraceptive for heavy menstrual bleeding approved in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...